Assessment of platelets and the endothelium in patients presenting with acute coronary syndromes – is there a future?

• References

• 1 Armstrong EJ, Morrow DA, Sabatine MS. Inflammatory biomarkers in acute coronary syndromes: part II: acute-phase reactants and biomarkers of endothelial cell activation. Circulation 2006; 113: e152-e155.
• 2 Armstrong EJ, Morrow DA, Sabatine MS. Inflammatory biomarkers in acute coronary syndromes: part IV: matrix metalloproteinases and biomarkers of platelet activation. Circulation 2006; 113: e382-e385.
• 3 Biasucci LM. CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: clinical use of inflammatory markers in patients with cardiovascular diseases: a background paper. Circulation 2004; 110: e560-e567.
• 4 Hurks R, Peeters W, Derksen WJ. et al. Biobanks and the search for predictive biomarkers of local and systemic outcome in atherosclerotic disease. Thromb Haemost 2009; 101: 48-54.
• 5 Deanfield JE, Halcox JP, Rabelink TJ. Endothelial function and dysfunction: testing and clinical relevance. Circulation 2007; 115: 1285-1295.
• 6 Langer HF, Gawaz M. Platelet-vessel wall interactions in atherosclerotic disease. Thromb Haemost 2008; 99: 480-486.
• 7 Constans J, Conri C. Circulating markers of endothelial function in cardiovascular disease. Clin Chim Acta 2006; 368: 33-47.
• 8 Mulvihill NT, Foley JB, Murphy RT. et al. Risk stratification in unstable angina and non-Q wave myocardial infarction using soluble cell adhesion molecules. Heart 2001; 85: 623-627.
• 9 Rallidis LS, Gika HI, Zolindaki MG. et al. Usefulness of elevated levels of soluble vascular cell adhesion molecule-1 in predicting in-hospital prognosis in patients with unstable angina pectoris. Am J Cardiol 2003; 92: 1195-1197.
• 10 Blann AD, Amiral J, McCollum CN. Prognostic value of increased soluble thrombomodulin and increased soluble E-selectin in ischaemic heart disease. Eur J Haematol 1997; 59: 115-120.
• 11 Blann AD, Woywodt A, Bertolini F. et al. Circulating endothelial cells. Biomarker of vascular disease. Thromb Haemost 2005; 93: 228-235.
• 12 Lee KW, Lip GY, Tayebjee M. et al. Circulating endothelial cells, von Willebrand factor, interleukin-6, and prognosis in patients with acute coronary syndromes. Blood 2005; 105: 526-532.
• 13 Quilici J, Banzet N, Paule P. et al. Circulating endothelial cell count as a diagnostic marker for non-ST-elevation acute coronary syndromes. Circulation 2004; 110: 1586-1591.
• 14 Boos CJ, Balakrishnan B, Blann AD. et al. The relationship of circulating endothelial cells to plasma indices of endothelial damage/dysfunction and apoptosis in acute coronary syndromes: implications for prognosis. J Thromb Haemost 2008; 06: 1841-1850.
• 15 Egan CG, Caporali F, Huqi AF. et al. Reduced levels of putative endothelial progenitor and CXCR4+ cells in coronary artery disease: Kinetics following percutaneous coronary intervention and association with clinical characteristics. Thromb Haemost 2009; 101: 1138-1146.
• 16 Wojakowski W, Kucia M, Kazmierski M. et al. Circulating progenitor cells in stable coronary heart disease and acute coronary syndromes: relevant reparatory mechanism?. Heart 2008; 94: 27-33.
• 17 Blann AD. Plasma von Willebrand factor, thrombosis, and the endothelium: the first 30 years. Thromb Haemost 2006; 95: 49-55.
• 18 Spiel AO, Gilbert JC, Jilma B. von Willebrand factor in cardiovascular disease: focus on acute coronary syndromes. Circulation 2008; 117: 1449-1459.
• 19 Collet JP, Montalescot G, Vicaut E. et al. Acute release of plasminogen activator inhibitor-1 in ST-segment elevation myocardial infarction predicts mortality. Circulation 2003; 108: 391-394.
• 20 Montalescot G, Philippe F, Ankri A. et al. Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease: beneficial effects of enoxaparin. French Investigators of the ESSENCE Trial. Circulation 1998; 98: 294-299.
• 21 Montalescot G, Collet JP, Lison L. et al. Effects of various anticoagulant treatments on von Willebrand factor release in unstable angina. J Am Coll Cardiol 2000; 36: 110-114.
• 22 Ray KK, Morrow DA, Gibson CM. et al. Predictors of the rise in vWF after ST elevation myocardial infarction: implications for treatment strategies and clinical outcome: An ENTIRE-TIMI 23 substudy. Eur Heart J 2005; 26: 440-446.
• 23 Montalescot G, Collet JP, Choussat R. et al. A rise of troponin and/or von Willebrand factor over the first 48 h is associated with a poorer 1-year outcome in unstable angina patients. Int J Cardiol 2000; 72: 293-294.
• 24 Sakai H, Goto S, Kim JY. et al. Plasma concentration of von Willebrand factor in acute myocardial infarction. Thromb Haemost 2000; 84: 204-209.
• 25 Andreotti F, Roncaglioni MC, Hackett DR. et al. Early coronary reperfusion blunts the procoagulant response of plasminogen activator inhibitor-1 and von Willebrand factor in acute myocardial infarction. J Am Coll Cardiol 1990; 16: 1553-1560.
• 26 Andreotti F, Hackett DR, Haider AW. et al. Von Willebrand factor, plasminogen activator inhibitor-1 and C-reactive protein are markers of thrombolytic efficacy in acute myocardial infarction. Thromb Haemost 1992; 68: 678-682.
• 27 Soskin P, Mossard JM, Arbogast R. et al. Variation in von Willebrand’s Factor according to the treatment of acute myocardial infarction: physiopathological and clinical implications. Eur Heart J 1994; 15: 479-482.
• 28 Empana JP, Canoui-Poitrine F, Luc G. et al. Contribution of novel biomarkers to incident stable angina and acute coronary syndrome: the PRIME Study. Eur Heart J 2008; 29: 1966-1974.
• 29 Paulinska P, Spiel A, Jilma B. Role of von Willebr and factor in vascular disease. Hamostaseologie 2009; 29: 32-38.
• 30 Vischer UM. von Willebrand factor, endothelial dysfunction, and cardiovascular disease. J Thromb Haemost 2006; 04: 1186-1193.
• 31 Spiel AO, Mayr F, Ladani N. et al. The Aptamer ARC1779 is a potent and specific inhibitor of von Willebrand factor mediated ex vivo platelet function in acute myocardial infarction. Platelets 2009; 20: 334-340.
• 32 Wadanoli M, Sako D, Shaw GD. et al. The von Willebrand factor antagonist (GPG-290) prevents coronary thrombosis without prolongation of bleeding time. Thromb Haemost 2007; 98: 397-405.
• 33 Crawley JT, Lane DA, Woodward M. et al. Evidence that high von Willebrand factor and low ADAMTS-13 levels independently increase the risk of a non-fatal heart attack. J Thromb Haemost 2008; 06: 583-588.
• 34 Gori AM, Marcucci R, Paniccia R. et al. Thrombotic events in high risk patients are predicted by evaluating different pathways of platelet function. Thromb Haemost 2008; 100: 1136-1145.
• 35 Campo G, Valgimigli M, Gemmati D. et al. Value of platelet reactivity in predicting response to treatment and clinical outcome in patients undergoing primary coronary intervention: insights into the STRATEGY Study. J Am Coll Cardiol 2006; 48: 2178-2185.
• 36 Foussas SG, Zairis MN, Tsirimpis VG. et al. The impact of aspirin resistance on the long-term cardiovascular mortality in patients with non-ST segment elevation acute coronary syndromes. Clin Cardiol 2009; 32: 142-147.
• 37 Frossard M, Fuchs I, Leitner JM. et al. Platelet function predicts myocardial damage in patients with acute myocardial infarction. Circulation 2004; 110: 1392-1397.
• 38 Fuchs I, Frossard M, Spiel A. et al. Platelet function in patients with acute coronary syndrome (ACS) predicts recurrent ACS. J Thromb Haemost 2006; 04: 2547-2552.
• 39 Malek LA, Spiewak M, Filipiak KJ. et al. Persistent platelet activation is related to very early cardiovascular events in patients with acute coronary syndromes. Kardiol Pol 2007; 65: 40-45.
• 40 Marcucci R, Paniccia R, Antonucci E. et al. Residual platelet reactivity is an independent predictor of myocardial injury in acute myocardial infarction patients on antiaggregant therapy. Thromb Haemost 2007; 98: 844-851.
• 41 Christie DJ, Kottke-Marchant K, Gorman RT. Hypersensitivity of platelets to adenosine diphosphate in patients with stable cardiovascular disease predicts major adverse events despite antiplatelet therapy. Platelets 2008; 19: 104-110.
• 42 Jilma B. Platelet function analyzer (PFA-100): a tool to quantify congenital or acquired platelet dysfunction. J Lab Clin Med 2001; 138: 152-163.
• 43 Krasopoulos G, Brister SJ, Beattie WS. et al. Aspirin “resistance” and risk of cardiovascular morbidity: systematic review and meta-analysis. Br Med J 2008; 336: 195-198.
• 44 Snoep JD, Hovens MM, Eikenboom JC. et al. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. Arch Intern Med 2007; 167: 1593-1599.
• 45 Sofi F, Marcucci R, Gori AM. et al. Residual platelet reactivity on aspirin therapy and recurrent cardiovascular events--a meta-analysis. Int J Cardiol 2008; 128: 166-171.
• 46 Reny JL, De Mauro P, Dauzat M. et al. Use of the PFA-100 closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: a systematic review and meta-analysis. J Thromb Haemost 2008; 06: 444-450.
• 47 Crescente M, Di Castelnuovo A, Iacoviello L. et al. Response variability to aspirin as assessed by the platelet function analyzer (PFA)-100. A systematic review. Thromb Haemost 2008; 99: 14-26.
• 48 Zimmermann N, Hohlfeld T. Clinical implications of aspirin resistance. Thromb Haemost 2008; 100: 379-390.
• 49 King III SB, Smith Jr. SC, Hirshfeld JW. et al. 2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf of the 2005 Writing Committee. Circulation 2008; 117: 261-295.
• 50 Gurbel PA, Bliden KP, Hiatt BL. et al. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003; 107: 2908-2913.
• 51 Sibbing D, Morath T, Stegherr J. et al. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb Haemost 2009; 101: 714-719.
• 52 Siller-Matula JM, Spiel AO, Lang IM. et al. Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am Heart J 2009; 157: 148-155.
• 53 Ajzenberg N, Aubry P, Huisse MG. et al. Enhanced shear-induced platelet aggregation in patients who experience subacute stent thrombosis: a case-control study. J Am Coll Cardiol 2005; 45: 1753-1756.
• 54 Barragan P, Bouvier JL, Roquebert PO. et al. Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation. Catheter Cardiovasc Interv 2003; 59: 295-302.
• 55 Blindt R, Stellbrink K, de Taeye A. et al. The significance of vasodilator-stimulated phosphoprotein for risk stratification of stent thrombosis. Thromb Haemost 2007; 98: 1329-1334.
• 56 Buonamici P, Marcucci R, Migliorini A. et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol 2007; 49: 2312-2317.
• 57 Frere C, Cuisset T, Quilici J. et al. ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome. Thromb Haemost 2007; 98: 838-843.
• 58 Geisler T, Langer H, Wydymus M. et al. Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur Heart J 2006; 27: 2420-2425.
• 59 Gurbel PA, Bliden KP, Samara W. et al. Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study. J Am Coll Cardiol 2005; 46: 1827-1832.
• 60 Hobson A, Curzen N. Improving outcomes with antiplatelet therapies in percutaneous coronary intervention and stenting. Thromb Haemost 2009; 101: 23-30.
• 61 Hobson AR, Petley G, Morton G. et al. Point-of-care platelet function assays demonstrate reduced responsiveness to clopidogrel, but not aspirin, in patients with Drug-Eluting Stent Thrombosis whilst on dual antiplatelet therapy. Thromb J 2008; 06: 1.
• 62 Morel O, Faure A, Ohlmann P. et al. Impaired platelet responsiveness to clopidogrel identified by flow cytometric vasodilator-stimulated phosphoprotein (VASP) phosphorylation in patients with subacute stent thrombosis. Thromb Haemost 2007; 98: 896-899.
• 63 Schafer A, Bonz AW, Eigenthaler M. et al. Late thrombosis of a drug-eluting stent during combined anti-platelet therapy in a clopidogrel nonresponsive diabetic patient: shall we routinely test platelet function?. Thromb Haemost 2007; 97: 862-865.
• 64 Sibbing D, Braun S, Morath T. et al. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol 2009; 53: 849-856.
• 65 Wenaweser P, Dorffler-Melly J, Imboden K. et al. Stent thrombosis is associated with an impaired response to antiplatelet therapy. J Am Coll Cardiol 2005; 45: 1748-1752.
• 66 Bonello L, Camoin-Jau L, Arques S. et al. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. J Am Coll Cardiol 2008; 51: 1404-1411.
• 67 Gremmel T, Steiner S, Seidinger D. et al. Comparison of methods to evaluate clopidogrel-mediated platelet inhibition after percutaneous intervention with stent implantation. Thromb Haemost 2009; 101: 333-339.
• 68 van Werkum JW, Harmsze AM, Elsenberg EH. et al. The use of the VerifyNow system to monitor antiplatelet therapy: a review of the current evidence. Platelets 2008; 19: 479-488.
• 69 Seyfert UT, Haubelt H, Vogt A. et al. Variables influencing Multiplate(TM) whole blood impedance platelet aggregometry and turbidimetric platelet aggregation in healthy individuals. Platelets 2007; 18: 199-206.
• 70 Dichiara J, Bliden KP, Tantry US. et al. Platelet function measured by VerifyNow identifies generalized high platelet reactivity in aspirin treated patients. Platelets 2007; 18: 414-423.
• 71 Harrison P, Segal H, Silver L. et al. Lack of reproducibility of assessment of aspirin responsiveness by optical aggregometry and two platelet function tests. Platelets 2008; 19: 119-124.
• 72 Marcucci R, Gori AM, Paniccia R. et al. Cardiovascular death and non-fatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month followup. Circulation 2009; 119: 237-242.
• 73 Valgimigli M, Campo G, de Cesare N. et al. Intensifying Platelet Inhibition With Tirofiban in Poor Responders to Aspirin, Clopidogrel, or Both Agents Undergoing Elective Coronary Intervention. Results From the Double-Blind, Prospective, Randomized Tailoring Treatment With Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel Study. Circulation 2009; 119: 3215-3222.
• 74 Oestreich JH, Smyth SS, Campbell CL. Platelet function analysis: at the edge of meaning. Thromb Haemost 2009; 101: 217-219.
• 75 Price MJ, Berger PB, Angiolillo DJ. et al. Evaluation of individualized clopidogrel therapy after drug-eluting stent implantation in patients with high residual platelet reactivity: design and rationale of the GRAVITAS trial. Am Heart J 2009; 157: 818-824.
• 76 Bigalke B, Stellos K, Stakos D. et al. Influence of platelet count on the expression of platelet collagen receptor glycoprotein VI (GPVI) in patients with acute coronary syndrome. Thromb Haemost 2009; 101: 911-915.
• 77 Grove EL, Hvas AM, Kristensen SD. Immature platelets in patients with acute coronary syndromes. Thromb Haemost 2009; 101: 151-156.
• 78 Vasan RS. Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation 2006; 113: 2335-2362.